|
A more recent version of this article appeared on June 1, 2005
Papers In Press, published online ahead of print March 16, 2005
J. Lipid Res., doi:10.1194/jlr.M400511-JLR200
Submitted on December 23, 2004
Revised on February 23, 2005
Accepted on March 3, 2005
Enzymatic characterization of recombinant human paraoxonases (PON1, PON2 and PON3) - lactonases with overlapping and distinct substrate specificities
Dragomir I. Draganov, John F. Teiber, Audrey Speelman, Yoichi Osawa, Roger Sunahara, and Bert N. La Du
Pharmacology Dept., University of Michigan, Ann Arbor, MI 48019-0632
Corresponding Author: draganov{at}umich.edu
The paraoxonase (PON) gene-family in humans has three members, PON1, PON2 and PON3. Their physiological role(s) and natural substrates are uncertain. We developed a baculovirus mediated expression system, suitable for all three human PONs, and optimized procedures for their purification. The recombinant PONs are glycosylated with high-mannose type sugars, which are important for protein stability, but are not essential for their enzymatic activities. Enzymatic characterization of the purified PONs has revealed them to be lactonases/lactonizing enzymes, with some overlapping substrates (e.g. aromatic lactones), but also having distinctive substrate specificities. All three PONs metabolized very efficiently 5-hydroxy-eicosatetraenoic acid 1,5 lactone and 4-hydroxy-docosahexaenoic acid, which are products of both enzymatic and non-enzymatic oxidation of arachidonic and docosahexaenoic acid, respectively, and may represent PONs endogenous substrates. Organophosphates are hydrolyzed almost exclusively by PON1, whereas bulky drug substrates such as lovastatin and spironolactone are hydrolyzed only by PON3. Of special interest is the ability of the human PONs, especially PON2, to hydrolyze and thereby inactivate N-acyl-homoserine lactones, which are quorum-sensing signals of pathogenic bacteria. None of the recombinant PONs protected low density lipoprotein against copper induced oxidation in vitro.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
D. A. Stoltz, E. A. Ozer, T. J. Recker, M. Estin, X. Yang, D. M. Shih, A. J. Lusis, and J. Zabner
A Common Mutation in Paraoxonase-2 Results in Impaired Lactonase Activity
J. Biol. Chem.,
December 18, 2009;
284(51):
35564 - 35571.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Zerrad-Saadi, P. Therond, S. Chantepie, M. Couturier, K.-A. Rye, M. J. Chapman, and A. Kontush
HDL3-Mediated Inactivation of LDL-Associated Phospholipid Hydroperoxides Is Determined by the Redox Status of Apolipoprotein A-I and HDL Particle Surface Lipid Rigidity: Relevance to Inflammation and Atherogenesis
Arterioscler Thromb Vasc Biol,
December 1, 2009;
29(12):
2169 - 2175.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Romani, G. E. De Medio, S. di Tullio, R. Lapalombella, I. Pirisinu, V. Margonato, A. Veicsteinas, M. Marini, and G. Rosi
Modulation of paraoxonase 1 and 3 expression after moderate exercise training in the rat
J. Lipid Res.,
October 1, 2009;
50(10):
2036 - 2045.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Rosenblat, R. Coleman, S. T. Reddy, and M. Aviram
Paraoxonase 2 attenuates macrophage triglyceride accumulation via inhibition of diacylglycerol acyltransferase 1
J. Lipid Res.,
May 1, 2009;
50(5):
870 - 879.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R.W. Browne, W.B. Shelly, M.S. Bloom, A.J. Ocque, J.R. Sandler, H.G. Huddleston, and V.Y. Fujimoto
Distributions of high-density lipoprotein particle components in human follicular fluid and sera and their associations with embryo morphology parameters during IVF
Hum. Reprod.,
August 1, 2008;
23(8):
1884 - 1894.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. J. Nicholls and S. L. Hazen
Homocysteine Levels, Paraoxonase 1 (PON1) Activity, and Cardiovascular Risk--Reply
JAMA,
July 9, 2008;
300(2):
169 - 169.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. F. Teiber, S. Horke, D. C. Haines, P. K. Chowdhary, J. Xiao, G. L. Kramer, R. W. Haley, and D. I. Draganov
Dominant Role of Paraoxonases in Inactivation of the Pseudomonas aeruginosa Quorum-Sensing Signal N-(3-Oxododecanoyl)-L-Homoserine Lactone
Infect. Immun.,
June 1, 2008;
76(6):
2512 - 2519.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-H. Dong, L.-H. Wang, and L.-H. Zhang
Quorum-quenching microbial infections: mechanisms and implications
Phil Trans R Soc B,
July 29, 2007;
362(1483):
1201 - 1211.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Gaidukov and D. S. Tawfik
The development of human sera tests for HDL-bound serum PON1 and its lipolactonase activity
J. Lipid Res.,
July 1, 2007;
48(7):
1637 - 1646.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. J. Ng, N. Bourquard, S. Y. Hama, D. Shih, V. R. Grijalva, M. Navab, A. M. Fogelman, and S. T. Reddy
Adenovirus-Mediated Expression of Human Paraoxonase 3 Protects Against the Progression of Atherosclerosis in Apolipoprotein E-Deficient Mice
Arterioscler Thromb Vasc Biol,
June 1, 2007;
27(6):
1368 - 1374.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. I. Draganov
Human PON3, Effects Beyond the HDL: Clues From Human PON3 Transgenic Mice
Circ. Res.,
April 27, 2007;
100(8):
1104 - 1105.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. M. Shih, Y.-R. Xia, X.-P. Wang, S. S. Wang, N. Bourquard, A. M. Fogelman, A. J. Lusis, and S. T. Reddy
Decreased Obesity and Atherosclerosis in Human Paraoxonase 3 Transgenic Mice
Circ. Res.,
April 27, 2007;
100(8):
1200 - 1207.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Stoltz, E. A. Ozer, C. J. Ng, J. M. Yu, S. T. Reddy, A. J. Lusis, N. Bourquard, M. R. Parsek, J. Zabner, and D. M. Shih
Paraoxonase-2 deficiency enhances Pseudomonas aeruginosa quorum sensing in murine tracheal epithelia
Am J Physiol Lung Cell Mol Physiol,
April 1, 2007;
292(4):
L852 - L860.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Kriska, G. K. Marathe, J. C. Schmidt, T. M. McIntyre, and A. W. Girotti
Phospholipase Action of Platelet-activating Factor Acetylhydrolase, but Not Paraoxonase-1, on Long Fatty Acyl Chain Phospholipid Hydroperoxides
J. Biol. Chem.,
January 5, 2007;
282(1):
100 - 108.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Gaidukov, M. Rosenblat, M. Aviram, and D. S. Tawfik
The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux
J. Lipid Res.,
November 1, 2006;
47(11):
2492 - 2502.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. Muh, M. Schuster, R. Heim, A. Singh, E. R. Olson, and E. P. Greenberg
Novel Pseudomonas aeruginosa Quorum-Sensing Inhibitors Identified in an Ultra-High-Throughput Screen
Antimicrob. Agents Chemother.,
November 1, 2006;
50(11):
3674 - 3679.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. C. Schanen
Epigenetics of autism spectrum disorders
Hum. Mol. Genet.,
October 15, 2006;
15(suppl_2):
R138 - R150.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. J. Ng, N. Bourquard, V. Grijalva, S. Hama, D. M. Shih, M. Navab, A. M. Fogelman, A. J. Lusis, S. Young, and S. T. Reddy
Paraoxonase-2 Deficiency Aggravates Atherosclerosis in Mice Despite Lower Apolipoprotein-B-containing Lipoproteins: ANTI-ATHEROGENIC ROLE FOR PARAOXONASE-2
J. Biol. Chem.,
October 6, 2006;
281(40):
29491 - 29500.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Saeed, N. Siddique, W. Y. Hung, E. Usacheva, E. Liu, R. L. Sufit, S. L. Heller, J. L. Haines, M. Pericak-Vance, and T. Siddique
Paraoxonase cluster polymorphisms are associated with sporadic ALS
Neurology,
September 12, 2006;
67(5):
771 - 776.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Kontush and M. J. Chapman
Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis
Pharmacol. Rev.,
September 1, 2006;
58(3):
342 - 374.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. S. Carlson, P. J. Heagerty, T. S. Hatsukami, R. J. Richter, J. Ranchalis, J. Lewis, T. J. Bacus, L. A. McKinstry, G. D. Schellenberg, M. Rieder, et al.
TagSNP analyses of the PON gene cluster: effects on PON1 activity, LDL oxidative susceptibility, and vascular disease
J. Lipid Res.,
May 1, 2006;
47(5):
1014 - 1024.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Khersonsky and D. S. Tawfik
The Histidine 115-Histidine 134 Dyad Mediates the Lactonase Activity of Mammalian Serum Paraoxonases
J. Biol. Chem.,
March 17, 2006;
281(11):
7649 - 7656.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Rosenblat, L. Gaidukov, O. Khersonsky, J. Vaya, R. Oren, D. S. Tawfik, and M. Aviram
The Catalytic Histidine Dyad of High Density Lipoprotein-associated Serum Paraoxonase-1 (PON1) Is Essential for PON1-mediated Inhibition of Low Density Lipoprotein Oxidation and Stimulation of Macrophage Cholesterol Efflux
J. Biol. Chem.,
March 17, 2006;
281(11):
7657 - 7665.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Gutierrez, E. P. Ratliff, A. M. Andres, X. Huang, W. L. McKeehan, and R. A. Davis
Bile Acids Decrease Hepatic Paraoxonase 1 Expression and Plasma High-Density Lipoprotein Levels Via FXR-Mediated Signaling of FGFR4
Arterioscler Thromb Vasc Biol,
February 1, 2006;
26(2):
301 - 306.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|